Arialys Therapeutics, Inc. filed a Form D with the Securities and Exchange Commission on 2025-07-01.
Arialys Therapeutics, Inc. filed a Form D notice of an exempt securities offering with the SEC on July 1, 2025. The filing reports $14.80M sold. Its industry group is Biotechnology. It names Jay Lichter, Ph.D. (Director), Brian Slingsby, M.D., Ph.D., M.P.H. (Director), Ed Hurwitz (Director) (SEC Form D, July 1, 2025).
Is this your company?
Sell to companies like Arialys Therapeutics, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
New Form D on file · 2025-07-01 · the record
Pitching, partnering or investing alongside them? See who really runs and owns Arialys Therapeutics, Inc.
Free to see. No signup.
More on the people and the money behind Arialys Therapeutics, Inc., from the filings we hold.
Biotechnology raises by companies based in California, filed in July 2025, largest first.
Get an email when Arialys Therapeutics, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
We'll show it in your MentionFox inbox when Arialys Therapeutics, Inc. raises, hires or launches. No email unless you switch it on.
Watch Arialys Therapeutics, Inc. →Get the full cited report on Arialys Therapeutics, Inc.
What the filing shows about Arialys Therapeutics, Inc.
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Arialys Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
The filing gives Arialys Therapeutics, Inc.'s address as 11099 North Torrey Pines Road, Suite 290, La Jolla, CA 92037.
Saved here on this device in the meantime, so nothing is lost either way.
This is the company's own disclosure. A payment disclosed on a Form D is a disclosed use of proceeds, not a finding of wrongdoing.
Order the Full Report on Arialys Therapeutics, Inc. See pricing
Arialys Therapeutics, Inc. is a registered filer with the SEC (CIK 1956823) and has filed since 2022-12-02. 2 filings are on record, the latest on 2025-07-01.
A filing shows the company exists and what it reports about itself. It is not an audit or a rating.
Arialys Therapeutics, Inc.'s Form D of 2025-07-01 names Jay Lichter, Ph.D., Brian Slingsby, M.D., Ph.D., M.P.H., Ed Hurwitz and 2 more as its officers, directors or promoters.
Its new offerings report $29.13M sold across 2 offerings, as its own filings state.
Each marker is one filing. The larger marker is the filing this page is about.
Trailing twelve months. 769 filings in Biotechnology, totalled by week.
Jay Lichter, Ph.D. is named as Director on the Form D that Arialys Therapeutics, Inc. filed with the SEC on 1 July 2025, one of 5 people that filing names.
Brian Slingsby, M.D., Ph.D., M.P.H. is named as Director on the Form D that Arialys Therapeutics, Inc. filed with the SEC on 1 July 2025, one of 5 people that filing names.
Ed Hurwitz is named as Director on the Form D that Arialys Therapeutics, Inc. filed with the SEC on 1 July 2025, one of 5 people that filing names.
Peter Flynn, Ph.D. is named as Executive Officer and Director on the Form D that Arialys Therapeutics, Inc. filed with the SEC on 1 July 2025, one of 5 people that filing names.
Ashish Xavier, Ph.D. is named as Director on the Form D that Arialys Therapeutics, Inc. filed with the SEC on 1 July 2025, one of 5 people that filing names.
5 people named on the filing — 1 holding an executive role and 4 as directors only.
Named as of the 2025-07-01 filing. Titles and locations are exactly as the filing states — not independently confirmed elsewhere.
No investor is drawn from a Form D — the form states how many invested and never who.
What the filing shows about Arialys Therapeutics, Inc.
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Arialys Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Arialys Therapeutics, Inc. covers
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
You land back on this company when you are in.
Not ready to upgrade? Keep this one in view instead.
Watchlist Arialys Therapeutics, Inc.You get an alert in MentionFox the next time this company shows up.
If you're behind Arialys Therapeutics, Inc.: the weeks after a raise are watched the same way — by other investors sizing you up, and by founders checking who just got funded. FoxPlug turns your commits, deploys, and releases into that story automatically. GetFoxChat puts a guide on your own site so the people this filing just sent you don't leave after one page.
Sourced from the filing index on sec.gov.
Each opens in a new tab, filled in for Arialys Therapeutics, Inc.. With no account yet, you sign up free and land on the result.
On these lists: Biotech raises in San Diego
Share your raise. This card is drawn from the company's own Form D filing, and sharing needs no account.
https://mentionfox.com/funding/arialys-therapeutics-inc-form-d-25000001